Stock Alert: Bellerophon Therapeutics (BLPH) Breathes Easy

(RTTNews) - The University Of Miami School Of Medicine has for the first time initiated treatment of a COVID-19 patient with Bellerophon Therapeutics Inc.'s (BLPH) INOpulse inhaled nitric oxide system under the emergency expanded access program.

On March 20, the FDA granted emergency expanded access that allows INOpulse to immediately be used for the treatment of COVID-19 under the care and supervision of their physician. The news sent the stock as high as 666% to $26 in intraday trading that day.

Roger Alvarez, Assistant Professor, University of Miami School of Medicine and treating physician, said, "The cardiopulmonary benefit demonstrated by INOpulse in various indications provides the potential to prevent deterioration in patients with COVID-19, allowing ventilators to be preserved for the most critically ill. INOpulse's ease of administration could significantly decrease the burden on therapists and nurses as they combat this pandemic with constrained resources."

In a phase II study, the results of which were reported in February of this year, INOpulse demonstrated its potential to become a transformative therapy for patients with Pulmonary Hypertension associated with Pulmonary Fibrosis (PH-PF). A phase III study of INOpulse in PH-PF is being planned.

BLPH has traded in a range of $3.19 to $26.00 in the last 1 year. The stock closed Friday's trading at $12.67, up 11.43%. In pre-market trading on Monday, BLPH is up more than 40% at $18.